Corcept Therapeutics (CORT) Return on Invested Capital (2017 - 2024)
Corcept Therapeutics (CORT) reported Return on Invested Capital of 0.06% for Q3 2024, up 4.0% on a YoY basis from 0.06% in Q4 2023, and up 89.32% sequentially from 0.03% in Q2 2024.
Corcept Therapeutics (CORT) Return on Invested Capital (2017 - 2024) Analysis & Trends
Corcept Therapeutics (CORT) has 4 years of Return on Invested Capital data on file, last reported at 0.06% in Q3 2024.
- For the quarter ending Q3 2024, Return on Invested Capital rose 4.0% year-over-year to 0.06%; the trailing twelve-month figure through Sep 2024 stood at 0.06% (up 4.0% YoY), and the FY2023 full-year result was 0.07%, changed N/A from the prior year.
- Return on Invested Capital rose to 0.06% in Q3 2024, from 0.03% in the prior quarter.
- In the past five years, Return on Invested Capital ranged from a high of 0.06% in Q3 2024 to a low of 0.02% in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.00% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.04% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Corcept Therapeutics | 10.09 Bn | 9.76 Bn | 162.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 0.06% |
| Jun 30, 2024 | 0.03% |
| Mar 31, 2024 | 0.02% |
| Dec 31, 2023 | 0.02% |
| Sep 30, 2023 | 0.02% |
| Jun 30, 2023 | 0.02% |
| Mar 31, 2023 | 0.04% |
| Mar 31, 2018 | 0.15% |
| Dec 31, 2017 | 0.03% |
| Sep 30, 2017 | 0.00% |
| Jun 30, 2017 | 0.00% |
| Mar 31, 2017 | 0.00% |